Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Freiburg im Breisgau, Germany Clinical Trials

A listing of Freiburg im Breisgau, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (6) clinical trials

Safety and Tolerability of TG1050: A Dose-finding Study

Methodology This is a double-blind, randomized, placebo-controlled, multi-cohort Phase 1/1b study in patients that are currently being treated for chronic HBV infection. For all cohorts, patients must be receiving antiviral treatment with either tenofovir disoproxil fumarate (TDF) or entecavir (ENT) for at least two years, and have their HBV infection ...

Phase

0.0 miles

Learn More »

Safety Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis

The drug being tested in this study is called ixazomib. Ixazomib is being tested to find a safe and well tolerated dose in participants with lupus nephritis. This study will look at side effects and lab results in participants who take ixazomib, along with the determination of the pharmacokinetics (PK). ...

Phase

0.0 miles

Learn More »

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

The aim of the study is to determine a recommended dose for F16IL2 in combination with BI 836858 in AML relapse after alloHSCT and investigating safety and tolerability of the combination regimen. Dose escalation will be guided by a Bayesian logistic regression model (BLRM) with overdose control that will be ...

Phase

0.0 miles

Learn More »

Study of IMCY-0098 in Patients With Recent Onset Type 1 Diabetes

This clinical study will evaluate the safety of an innovative approach expected to be disease-modifying by stopping the auto-immune-mediated destruction of islet -cells in the pancreas. Three doses of the investigational product will be tested in successive cohorts. Although safety is the first objective of this study, we will gather ...

Phase

0.0 miles

Learn More »

Phase 1 Trial of MSC2490484A an Inhibitor of a DNA-dependent Protein Kinase in Combination With Radiotherapy

MSC2490484A or M3814 is an investigational drug that is being evaluated for the treatment of subjects with locally advanced tumors. The main purposes of this study are to determine the safety, the tolerability and the efficacy of MSC2490484A in combination with radiotherapy and in combination with chemoradiotherapy (Radiotherapy + cisplatin).

Phase

0.43 miles

Learn More »

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

This is a Phase I, open-label, dose-escalation trial with consecutive parallel-group expansion in selected solid tumor indications. The current trial is composed of a standard dose escalation "3 + 3" cohort design, for which 3 to 6 subjects will be enrolled at each dose level depending on the occurrence of ...

Phase

0.43 miles

Learn More »